NCT05901636View on ClinicalTrials.gov

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions

Influenza Prevention

Interventions

BIOLOGICAL

INFLUENZA G1 mHA

INFLUENZA G1 mHA will be administered intramuscularly.

BIOLOGICAL

Placebo

Placebo will be administered intramuscularly.

BIOLOGICAL

Al(OH)3

Al(OH)3 will be administered intramuscularly.

Trial Locations (4)

33016

Floridian Clinical Research LLC, Miami Lakes

45212

CTI Clinical Trial and Consulting Services, Cincinnati

66219

Johnson County Clin-Trials, Lenexa

70006

Clinical Trials Managements, LLC, Metairie

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT05901636 - A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults | Biotech Hunter | Biotech Hunter